Tag: system

The digital pathology market is segmented by product type into scanners, storage systems, and software. In 2024, scanners led the segment due to their pivotal role in converting glass slides to digital images, enhancing remote diagnostics. Human pathology is forecasted to dominate during the period, driven by global chronic disease burdens, necessitating accurate diagnostics. The rise of AI and machine learning in processing digital images boosts efficiency and diagnostic precision. North America is set to lead the market, fostered by a supportive regulatory framework and financial backing for innovation. Key players include Danaher, Philips, and F. Hoffmann-La Roche, among others. This comprehensive report provides in-depth insights into market drivers, opportunities, and competitive assessments across regions.

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Verizon Communications Inc. (“Verizon”) (NYSE, Nasdaq: VZ) today announced the commencement of two related transactions to repurchase 10 series of its outstanding notes listed in the tables below.

Large-scale testing by Fluence and CSA Group shows Gridstack Pro 5000 system, delivering up to 5.6 MWh in a 20-foot enclosure, surpassing current and emerging safety standards 

VALENCIA, Spain, June 12, 2025 (GLOBE NEWSWIRE) -- Turbo Energy S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global provider of leading-edge, AI-optimized solar energy storage technologies and solutions, today announced that it has been granted a new patent for its innovative system designed to integrate energy storage and expand photovoltaic generation in upstream installations. The patented system provides a unique method for enhancing energy efficiency and flexibility in self-consumption solar power systems—particularly those configured to prevent surplus energy from being injected into the electrical grid.

REVEAL Ultra Cellular Trail Camera is Company’s Most Feature-Rich Product to Date

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte^®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.